Photo Gallery



News & Updation

  • APRIL 2019 Issue has been successfully launched on 1 April 2019

  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from 6.647 to 7.421 due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.



*Dr. Manjula K., Pharma.D, Dr. K. Swapna, Pharma.D, Dr. E. Trivikram, Pharma.D, Dr. Aqueela Masood and Tahmina Sultana


Chronic kidney disease (CKD) is the 12th and 17th leading cause of death and disability globally, respectively. Almost 60% of the deaths worldwide are due to CKD and ~80% of deaths occur in low and middle income countries. The kidney cells that make erythropoietin are sensitive to low oxygen levels in the blood that travels through the kidney. These cells make and release erythropoietin when the oxygen level is too low. A low oxygen level may indicate a diminished number of red blood cells (anemia), or hemoglobin molecules that carry oxygen through the body. Anemia can happen early in the course of kidney disease and grow worse as kidney fail and can no longer produce Erythropoeitin. Anemia in CKD Patients is commonly treated with Erythropoietin stimulating agents (ESAs), Erythropoietin (Conventional &Pegylated), Epoietin beta methoxy polyethylene glycol, Epoietin (alpha & beta), Darbapoeitin. A total number of 60 Patients with CKD were screened out of which, 30 patients with Anaemia receiving Regular Erythropoietin were compared with another 30 patients receiving Mircera. Out of 30 patients receiving mircera 76.6% of patients using mircera were males and 23.3% were females. The past medical history of the patients were recorded and found that 93.3% were with HTN, 70% were with DM and 70% were having both HTN and DM. 40% of patients receiving mircera were recorded without any ADR’s. The increase in haemoglobin value was found to be 1.55 % in patients using erythropoietin with 37% of no ADR’s recordance compared to the patients using mircera whose increase in haemoglobin was 2.1% with 50 % of no ADR recordance. The ADR’s of 30 patients receiving erythropoietin are 37% of patients were of no ADR and 23% with fever 17% with nausea 10% cough 7% vomiting others diarrhea and dizziness 6.6%.The ADR’s of 30 patients receiving mircera are 50% of patients were of no ADR and 13.3% with HTN 10% with diarrhea 10% headache 6.6% cough others URTI and nasopharyngitis 10%.

Keywords: Chronic Kidney Disease, Regular Erythropoietin, Epoietin Beta Methoxy Polyethylene Glycol, Haemodialysis.

[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More